MedTrace Logo

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

NCT00917293 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2019-02-15

No results posted yet for this study

Summary

The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.

Conditions

  • Tardive Dyskinesia

Interventions

DRUG

Pyridoxal 5'-Phosphate

Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.

DRUG

Placebo

Placebo 2 pills, po bid.

Sponsors & Collaborators

  • Medicure

    lead INDUSTRY

Principal Investigators

  • Gary J. Remington, MD, PhD · Centre for Addiction and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-08-31
Completion
2014-08-31

Countries

  • Canada
  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917293 on ClinicalTrials.gov